Skye Bioscience Showcases Anti-Obesity Drug Nimacimab at ADA Conference, Highlights Safer CB1 Approach

Skye Bioscience, Inc. (NASDAQ:SKYE) ("Skye"), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today announced the debut of its "Anatomy of Progress" nimacimab development update video series and availability of presentations related to the development of its anti-obesity drug, nimacimab, presented in multiple forums at the American Diabetes Association's (ADA) 85th Scientific Sessions held June 20-23, 2025, in Chicago, Illinois. The presentations are accessible at the following link.

Skye Video Series: "Anatomy of Progress"

In this four-part video series highlighted below, Skye discusses unmet needs in the obesity therapeutic space, advantages and benefits of its peripheral CB1-receptor-targeting antibody, which is designed to support healthy weight loss, and development progress of this novel CB1-inhibiting molecule.

Skye's Chief Executive Officer, Punit Dhillon, commented on the important mechanistic advantages of nimacimab versus other CB1 inhibitors highlighted in this video update series: "Obesity isn't just a public health crisis, it's a biologically defended state, one that resists traditional treatments requiring smarter and safer interventions.

"At Skye, we're developing nimacimab, a CB1 antibody that targets receptors in the periphery, while remaining greater than 99% excluded from the brain. Unlike the small molecule CB1 inhibitors currently in development, nimacimab's differentiating peripheral restriction has the potential to demonstrate the same weight loss and metabolic benefits previously seen in clinical trials by first-generation CB1 inhibitors, without the significant neuropsychiatric liabilities that continue to plague its small molecule counterparts. So nimacimab is not just another anti-obesity drug, it represents a new frontier in how we think about fat metabolism, safety and long-term care."

The Anatomy of Progress video series is comprised of:

• Overview – Highlights Skye's positioning and progress in the obesity landscape, noting the differentiation of its allosteric modulating antibody.
  
  
  
   
• Chapter 1: Nimacimab – A Differentiated CB1 Inhibitor for Obesity – A review of Skye's highly peripherally-restricted CB1 inhibitor and its potential advantages relative to the incretin class of anti-obesity drugs and small-molecule CB1 inhibitors, with recent preclinical data.
  
  
  
   
• Chapter 2: Nimacimab in the Clinic – Reviews Skye's current clinical activity and near-term Phase 2a clinical data readouts.
  
  
  
   
• Chapter 3: Market Opportunity for Nimacimab – Discusses input from obesity physicians that frames the distinct opportunity for a non-GLP1 obesity therapeutic with nimacimab's target product profile.